Home › Lupus Nephritis
Lupus Nephritis clinical trials recruiting in the U.S.
33 studies for Lupus Nephritis are recruiting participants at sites across the United States.
Cities with the most studies
- New York City, NY10 studies
- Atlanta, GA9 studies
- Chicago, IL9 studies
- Durham, NC8 studies
- Houston, TX8 studies
- Boston, MA7 studies
- San Francisco, CA7 studies
- Philadelphia, PA7 studies
- St. Louis, MO5 studies
- Miami, FL5 studies
- Aurora, CO5 studies
- Dallas, TX4 studies
- Cleveland, OH4 studies
- Los Angeles, CA4 studies
- Syracuse, NY4 studies
- Charlotte, NC4 studies
- Charleston, SC4 studies
- Jacksonville, FL4 studies
- Santa Monica, CA3 studies
- Worcester, MA3 studies
- Washington, DC3 studies
- Baltimore, MD3 studies
- New Orleans, LA3 studies
- Johns Creek, GA3 studies
- Columbus, OH3 studies
- Gainesville, FL3 studies
By state
- Arizona3 studies
- California15 studies
- Colorado7 studies
- Florida10 studies
- Georgia11 studies
- Illinois9 studies
- Kansas3 studies
- Louisiana5 studies
- Maryland5 studies
- Massachusetts8 studies
- Michigan3 studies
- Minnesota3 studies
- Missouri6 studies
- New Jersey5 studies
- New York16 studies
- North Carolina11 studies
- Ohio7 studies
- Pennsylvania7 studies
- South Carolina4 studies
- Tennessee4 studies
- Texas12 studies
Recently updated studies
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
RecruitingPhase 3
Ages 18 to 100 · All sexes · Updated Sep 28, 2026 · NCT06711887CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
RecruitingPhase 1/2
Ages 10 to 29 · All sexes · Updated Sep 24, 2026 · NCT06839976A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
RecruitingPhase 2
Ages 16 to 70 · All sexes · Updated Sep 17, 2026 · NCT07328581VIBRANT: VIB4920 for Active Lupus Nephritis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT05201469Study of Systemic Lupus Erythematosus
RecruitingObservational studyHealthy volunteers welcome
Ages 3 to 120 · All sexes · Updated Sep 16, 2026 · NCT00001372Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
RecruitingPhase 1
Ages 18 to 60 · All sexes · Updated Sep 14, 2026 · NCT06975787The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
RecruitingPhase 2
Ages 8 to 20 · All sexes · Updated Sep 14, 2026 · NCT05538208A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
RecruitingPhase 2
Ages 12 to 70 · All sexes · Updated Sep 14, 2026 · NCT07570862A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
RecruitingPhase 1
Ages 18 to 74 · All sexes · Updated Sep 10, 2026 · NCT07085104A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Sep 10, 2026 · NCT06897930A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
RecruitingPhase 2
Ages 5 to 17 · All sexes · Updated Sep 3, 2026 · NCT05039619A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Aug 28, 2026 · NCT06925542RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RecruitingPhase 1/2
Ages 18 to 65 · All sexes · Updated Aug 26, 2026 · NCT06121297Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
RecruitingPhase 2
Ages 12 to 65 · All sexes · Updated Aug 24, 2026 · NCT07053800A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
RecruitingPhase 2
Ages 16 and older · All sexes · Updated Aug 4, 2026 · NCT06419205PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
RecruitingPhase 4
Ages 18 to 75 · All sexes · Updated Aug 3, 2026 · NCT07611214Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Jul 30, 2026 · NCT05268289A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jul 30, 2026 · NCT07201129Wellness & Workforce Solution for Lupus/Lupus Nephritis
RecruitingHealthy volunteers welcome
Ages 18 and older · Women · Updated Jul 24, 2026 · NCT06217107A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT07115745Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jul 2, 2026 · NCT06527872US Zamto-cel Autoimmune Diseases
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 11, 2026 · NCT06708845A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
RecruitingPhase 1/2
Ages 18 to 75 · All sexes · Updated Jun 4, 2026 · NCT06557265Dapagliflozin in Active Lupus Nephritis
RecruitingPhase 4
Ages 18 to 70 · All sexes · Updated May 26, 2026 · NCT07323524A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
RecruitingPhase 1
Ages 12 to 70 · All sexes · Updated May 22, 2026 · NCT06308978From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.